Simcere acquires Master Luck

Simcere said that through this transaction it has acquired the market-leading chemotherapeutic drug Jiebaisu and is enriching its anticancer product portfolio. In addition, it has acquired a specialized and high GMP standard chemotherapy production facility.

Simcere will combine Tung Chit’s anticancer chemotherapeutic R&D capabilities with Endu’s post-launch research team to explore other potential chemotherapeutic combo-treatments as an alternative to Endu’s existing combination with vinorelbine plus cisplatin.

Simcere will also leverage its existing well-established Endu’s marketing resources and network to increase Jiebaisu’s hospital penetration, market share and sales revenue.

Jinsheng Ren, chairman, CEO and founder of Simcere, said: “We are delighted to have Tung Chit join Simcere. As a new-generation, broad spectrum and highly effective platinum based anticancer drug, nedaplatin has been recognized by the industry to have better efficacy but less side-effects than cisplatin and carboplatin. We believe nedaplatin has strong growth prospects in China. This transaction enriches our anticancer product portfolio and strengthens our leading position in oncology so that we can better serve our patients.”